The following is a summary of “Feasibility of trancutaneous auricular vagus nerve stimulation in Black and Hispanic/Latino people with peripheral neuropathy,” published in the January 2025 issue of ...
The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...
The multi-site clinical trial finds significant improvements in pain, sensation, and nerve signaling. "Neuropathy is incredibly common among the aging population, regardless of disease states.
The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid ...
Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on LXRX stock, giving a Buy rating yesterday.Invest with Confidence: ...
Zacks.com on MSN11d
VRTX Gets FDA Nod for Non-Opioid Pain Drug Journavx, Shares UpThe FDA approves Vertex's non-opioid oral pain signal inhibitor, Journavx, for treating adults with moderate-to-severe acute pain. Shares rise.
Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.
Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback